enGene (NASDAQ: ENGN)
$3.15
(-4.3%)
-$0.14
Price as of June 20, 2025, 4:00 p.m. ET
enGene Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
enGene Company Info
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.